Enlivex Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENLV research report →
Range $15 – $15
Price Chart
About the company
Enlivex Therapeutics Ltd. , established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic.
- CEO
- Oren Hershkovitz
- IPO
- 2014
- Employees
- 34
- HQ
- Ness Ziona, TA, IL
Get TickerSpark's AI analysis on ENLV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $25.25M
- P/E
- 0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -1.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 248.08%
- ROIC
- -0.49%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-332,000+39.1%
- Op Income
- $-15,000,000
- Net Income
- $1.24B+8329.2%
- EPS
- $405.60+3804.1%
- OCF Growth
- +19.9%
- FCF Growth
- +20.0%
- 52W High
- $27.15
- 52W Low
- $1.46
- 50D MA
- $5.63
- 200D MA
- $12.08
- Beta
- 1.47
- RSI (14)
- 18
- Avg Volume
- 182.18K
No earnings-call transcripts are available for ENLV yet.
- Free Float
- 99.5%
- Shares Outstanding
- 16.83M
- Float Shares
- 16.75M
of shares held by institutions
27 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Skyview Investment Advisors, LLC | 10.00K | 0 |
| Red Tortoise LLC | 150 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Hershkovitz Oren | other | 0 |
| Nov 16, 23 | Hershkovitz Oren | other | 150,000 |
| Nov 24, 25 | Hershkovitz Oren | other | 60,000 |
| Mar 18, 26 | Shlosberger Shachar | other | 0 |
| Mar 7, 21 | Shlosberger Shachar | other | 1,452 |
| Dec 12, 21 | Shlosberger Shachar | other | 1,452 |
| Mar 30, 24 | Shlosberger Shachar | other | 5,000 |
| Dec 10, 22 | Shlosberger Shachar | other | 1,452 |
| Nov 24, 25 | Shlosberger Shachar | other | 10,000 |
| Nov 24, 25 | Shlosberger Shachar | other | 7,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENLV coverage
Recent articles, reports, and earnings notes.
No research on ENLV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENLV report →Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
globenewswire.com · Jul 30
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
globenewswire.com · Jul 29
Enlivex Announces $400,000,000 Private Placement
globenewswire.com · Jul 28
Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)
defenseworld.net · Jul 22
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
globenewswire.com · Jul 20
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
zacks.com · Jul 13
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com · Jul 13
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
globenewswire.com · Jul 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.